125 related articles for article (PubMed ID: 17267660)
1. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.
Sheffer Y; Leon O; Pinthus JH; Nagler A; Mor Y; Genin O; Iluz M; Kawada N; Yoshizato K; Pines M
Mol Cancer Ther; 2007 Feb; 6(2):570-7. PubMed ID: 17267660
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression.
Pinthus JH; Sheffer Y; Nagler A; Fridman E; Mor Y; Genina O; Pines M
J Urol; 2005 Oct; 174(4 Pt 2):1527-31. PubMed ID: 16148645
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of prostate cancer xenografts by halofuginone.
Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
Prostate; 2002 May; 51(2):73-83. PubMed ID: 11948962
[TBL] [Abstract][Full Text] [Related]
4. Halofuginone improves muscle-cell survival in muscular dystrophies.
Bodanovsky A; Guttman N; Barzilai-Tutsch H; Genin O; Levy O; Pines M; Halevy O
Biochim Biophys Acta; 2014 Jul; 1843(7):1339-47. PubMed ID: 24703880
[TBL] [Abstract][Full Text] [Related]
5. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
6. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.
Turgeman T; Hagai Y; Huebner K; Jassal DS; Anderson JE; Genin O; Nagler A; Halevy O; Pines M
Neuromuscul Disord; 2008 Nov; 18(11):857-68. PubMed ID: 18672370
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of rat renal fibroblast proliferation by halofuginone.
Haran N; Leschinski L; Pines M; Rapoport J
Nephron Exp Nephrol; 2006; 104(1):e35-40. PubMed ID: 16735800
[TBL] [Abstract][Full Text] [Related]
9. Targeting TGFβ signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginone.
Pines M
Expert Opin Drug Discov; 2008 Jan; 3(1):11-20. PubMed ID: 23480137
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
Huang SF; Kim SJ; Lee AT; Karashima T; Bucana C; Kedar D; Sweeney P; Mian B; Fan D; Shepherd D; Fidler IJ; Dinney CP; Killion JJ
Cancer Res; 2002 Oct; 62(20):5720-6. PubMed ID: 12384530
[TBL] [Abstract][Full Text] [Related]
11. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
12. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
McGaha TL; Phelps RG; Spiera H; Bona C
J Invest Dermatol; 2002 Mar; 118(3):461-70. PubMed ID: 11874485
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of Par-4 combined with cisplatin on human Wilms' tumor cells.
Wang J; Li Y; Ma F; Zhou H; Ding R; Lu B; Zou L; Li J; Lu R
Tumour Biol; 2017 Jul; 39(7):1010428317716689. PubMed ID: 28720068
[TBL] [Abstract][Full Text] [Related]
14. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
[TBL] [Abstract][Full Text] [Related]
15. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Elkin M; Ariel I; Miao HQ; Nagler A; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Cancer Res; 1999 Aug; 59(16):4111-8. PubMed ID: 10463616
[TBL] [Abstract][Full Text] [Related]
17. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism.
McGaha TL; Kodera T; Spiera H; Stan AC; Pines M; Bona CA
Arthritis Rheum; 2002 Oct; 46(10):2748-61. PubMed ID: 12384935
[TBL] [Abstract][Full Text] [Related]
18. Adult Wilms' tumor. Report of two cases and review of the literature.
Hentrich MU; Meister P; Brack NG; Lutz LL; Hartenstein RC
Cancer; 1995 Jan; 75(2):545-51. PubMed ID: 7812923
[TBL] [Abstract][Full Text] [Related]
19. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model.
Vernet D; Ferrini MG; Valente EG; Magee TR; Bou-Gharios G; Rajfer J; Gonzalez-Cadavid NF
Nitric Oxide; 2002 Dec; 7(4):262-76. PubMed ID: 12446175
[TBL] [Abstract][Full Text] [Related]
20. A promotive effect for halofuginone on membrane repair and synaptotagmin-7 levels in muscle cells of dysferlin-null mice.
Barzilai-Tutsch H; Dewulf M; Lamaze C; Butler Browne G; Pines M; Halevy O
Hum Mol Genet; 2018 Aug; 27(16):2817-2829. PubMed ID: 29771357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
